Huge carmaker ‘may sell iconic luxury motor brand' as sales dive and new CEO takes charge
Discussions over the
future
of Maserati remain ongoing as industry giant Stellantis prepares to welcome its new CEO in the coming days.
Advertisement
5
Discussions over the future of Maserati remain ongoing
Credit: Alamy
5
Stellantis could be forced to sell the luxury car brand
Credit: Reuters
5
Last year, the number of Maserati units sold plunged from 26,600 to just 11,300
Credit: Alamy
The French-Italian company could be forced to sell the luxury car brand on the back of poor sales over the past year.
New CEO Antonio Filosa - who starts on Monday after being appointed last month - faces huge financial decisions as a result of President Trump's brutal trade tariffs.
Stellantis - which owns 14 brands across the globe - was
McKinsey was called in April this year to advise on struggling brands Maserati and Alfa Romeo, with both experiencing a dire 2024.
Advertisement
Read more in Motors
Last year, the number of Maserati units sold plunged from 26,600 to just 11,300.
Stellanis told
: "McKinsey has been asked to provide its considerations regarding the recently announced U.S. tariffs for Alfa Romeo and Maserati."
Trump's new legislation means tariffs of at least 25 percent on anything imported into the US.
Maserati has no new model launches scheduled as it
waits for a new business plan
, with the last one having been put on hold by Stellantis in 2024.
Advertisement
Most read in Motors
The plan is expected to be presented soon after Filosa starts his new role.
But as things stand, it is understood that all options remain on the table for the world-renowned Italian brand.
It came after the global firm pulled the plug on a £1.3billion investment in Maserati earlier this year.
Advertisement
WHO ARE STELLANTIS?
The EV, which translates to 'lightning' in Italian, was intended to be the brand's electric alternative to the stunning MC20 sports car.
It promised a
power
output and performance characteristics similar to the existing V6-engined MC20
.
The Folgore
was set to be one of six Maserati EVs set for launch over the
next
year or so.
But Stellantis chief financial officer Doug Ostermann said they had pulled the plug on Maserati projects, claiming they wanted to review the pace in which sports car owners move over to EVs.
Advertisement
He said: "We have to recognise the dynamics in that business, particularly in the Chinese market, and our expectations in terms of how quickly that luxury market would transition to electrification."
What is Stellantis?
Stellantis is the company behind iconic motor brands such as Fiat, Vauxhall and Peugot.
The conglomerate, which is the second-largest maker of cars in Europe, owns 14 badges, including Chrysler, Citroen, Jeep and Maserati.
The company itself is the product of a merger between Fiat-Chrysler and France's PSA, the maker of Peugeot and Citroen, in 2021.
But the motoring giant has encountered increasingly stuttering financial success.
And an initial manufacturing break at Stellantis has now been extended as bosses report a collapse in
demand for electric cars
.
Other projects, including EV replacements for the Levante and Quattroporte
models
, are in danger of being cancelled too.
The vehicles were set to be released in 2027 and 2028 respectively.
It is understood the three models would have been Maserati's electric line-up as the firm looked to adapt to the EV revolution.
Advertisement
Before he left the firm last year, Stellantis boss Carlos Tavares claimed the low sales at Maserati were due to advertising issues.
He told Top Gear: "Maserati is in the red. The reason is marketing.
"The Maserati brand is not clearly positioned and the storytelling is not how it should be.
"The brand is not just about sports cars, it's about gran turismo, it's about quality of life, dolce vita and technology."
Advertisement
5
Former Stellantis boss Carlos Tavares said the low sales at Maserati were due to advertising issues
Credit: Alamy
5
Maserati has no new model launches scheduled as it waits for a new business plan
Credit: Alamy
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
2 minutes ago
- Irish Times
Export figures are hard to interpret right now, given flux around tariffs
It's hard to know where the State's trade with the US will land once the tariff impact has been digested. There's a lag effect to these levies combined with an uncertainty as to who will ultimately bear the cost. Trump and his Maga operatives are acting as if the burden falls totally outside the US and are boasting about the billions of dollars the US exchequer is likely to garner. But precedent suggests the tariff hit tends to fall on importing firms and ultimately domestic consumers. That's why everyone is looking at the US economy for signs of a slowdown. In the interim, we've got volatile trade numbers. The latest figures from the Central Statistics Office (CSO) show the value of exports from Ireland to the US fell by whopping 60 per cent between May and June, dropping from €10.8 billion to €4.4 billion. READ MORE The headline June figure was also down by a quarter on the same month last year. Most of this merely reflects a levelling of the surge seen in the earlier part of the year when firms rushed to stockpile goods in the US in advance of Trump's Liberation Day tariff announcement on April 2nd. The trade will presumably find its level once all this settles down. The European Union and the Government will be hoping for a manageable decline. From Ireland's perspective, the 15 per cent tariff on pharma , the main element of the State's export trade with the US, represents damage but controlled damage in the context of the US's retreat from free trade. Pharma firms here make big profits, big enough to absorb the hit without uprooting themselves. These companies work around 10-year cycles of investment and are therefore unlikely to jump ship on the whim of one of Trump's policy announcements. The biggest buyer of pharma is state healthcare and therefore much of the trade is inelastic, less sensitive to price changes. That's probably why Trump, in parallel to tariffs, is demanding these firms reduce their prices in the US. His threat to hike tariffs on EU pharma imports up to 250 per cent within a few years flies in the face of the EU-US trade deal and any notion of certainty it might signify. But that's the world we're in at the moment and why the CSO and other data points are so volatile.
Irish Independent
an hour ago
- Irish Independent
Irish brewer founded by Smithwick's family becomes second to shift operations stateside to escape Trump tariffs
An Irish beer brand revived by Smithwick's has moved most of its brewing to the US in response to the 15pc tariff President Donald Trump has put on EU imports The decision by Sullivan's Brewing Company, a Kilkenny beer brand co-founded by Dan and Alan Smithwick in 2016, comes as big pharmaceutical and technology companies seek to woo Trump by announcing largescale investments in the US. Earlier this month Apple struck a deal with Trump to invest $600bn (€515bn) in the US over the next four years to foster an 'end-to-end' American chip supply chain.
Irish Independent
an hour ago
- Irish Independent
Pharma companies warned Government over competitiveness before Trump's tariff war began
Multinationals criticised the impact of EU rules on how they do business Major pharmaceutical companies raised concerns about Ireland's competitiveness, ahead of Donald Trump's opening shots in early April which began the tariff war with the EU. Correspondence released under the Freedom of Information Act to the Sunday Independent show that companies called on the Government to address supply chain issues and ensure there was a diverse and skilled workforce here. They also criticised the impact of EU regulations on how they do business. The warnings from Eli Lilly and Johnson & Johnson came before Mr Trump heightened uncertainty in the sector by announcing sweeping global trade tariffs, and underlined the need for Ireland to react if it is to retain its significant foreign direct investment from the pharma sector. Multinational pharmaceutical companies play a significant role in Ireland's economy. IDA Ireland data shows more than 90 pharmaceutical companies are based here and provide in the region of 45,000 jobs. They also pay billions in corporation tax. US-headquartered Eli Lilly, which employs 3,500 people in Limerick, Cork and on a nationwide commercial team, met with Department of Enterprise officials in February and outlined their concerns around the future of the EU-US trading relationship. Meanwhile, Johnson & Johnson told Enterprise Minister Peter Burke that policy enhancements for business, health and housing 'should be considered in a co-ordinated manner that reflects national strategic priorities'. Trump has threatened future tariffs of between 150pc and 250p on pharma Notes from the Eli Lilly meeting show it told Department of Enterprise and IDA Ireland officials that it wants to see 'greater intensity from Ireland at EU level, specifically around the EU pharmaceutical legislation.' New EU pharma rules, which may be adopted by the end of this year, are designed to address issues around the availability of medicines, how they are produced, and aim to improve competitiveness in the sector. But some businesses raised concerns about the protections for clinical data before it is made available to the manufacturers of cheaper generic versions of drugs. Existing rules allow pharma companies to keep clinical data for eight years. Reforms would reduce this period to six years, although extensions may apply in some scenarios. Officials here said they recognised the need to strike a balance between access to affordable medicines and incentivising innovation. Notes from the Eli Lilly meeting show officials in the Department of Enterprise acknowledged EU-US trade concerns in the pharma sector, saying 'predictability is key for business' and that European engagement would be 'bolstered by expertise from industry'. The company 'also highlighted the importance of de-risking supply chains, ensuring there is a diverse skillset in Irish operations' and said that it 'would like to see more regulation co-operation between the US and EU, especially with the US Food and Drug Administration,' meeting notes stated. A letter sent to Mr Burke by Michaela Hagenhofer, Johnson & Johnson's general manager of commercial operations in Ireland, raised concerns about the European Commission proposing 'to weaken intellectual property incentives for pharmaceuticals… from eight years to six'. The letter stated: 'At European level, it is important that Ireland secures and strengthens its reputation as a life sciences hub by advocating for a competitive business environment. In recent decades, Europe's share of pharmaceutical investment has significantly declined.' A Department of Enterprise spokesman said it supports protecting intellectual property 'and will continue to make the case for this at EU level'. The EU and US last month agreed a 15pc tariff rate would apply on most European goods imported to America. Pharmaceutical goods are not currently the subject of this tariff, but the US is examining its drug supply chains, and levies could be imposed once that analysis concludes. European Commission president Ursula von der Leyen has said any future pharma tariffs would be capped at 15pc. Trump indicated this cap may only be maintained for 'one year, one-and-a-half years maximum' and threatened future rates of between 150pc and 250pc unless pharma companies return production to the US. 'The department welcomes an agreement that will provide much needed certainty to businesses which operate in Ireland and will continue to engage with the Department of Foreign Affairs and the European Commission,' a Department of Enterprise spokesman said. 'The Department has favoured a zero-for-zero arrangement and will continue to argue against any tariffs which may interfere with the closely integrated nature of the Irish and US pharmaceutical sectors.'
